Tenaya Therapeutics, Inc. — FY 2022 Form 10-K
Reporting period: Year ended December 31, 2022; filed March 8, 2023. Tenaya is a clinical-stage biotechnology company developing therapies for heart disease. It had no approved products and generated no product revenue.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $94.5 million | $54.4 million |
| General and administrative expense | $31.1 million | $18.4 million |
| Total operating expenses | $125.6 million | $72.8 million |
| Net loss | $123.7 million | $72.7 million |
| Net cash used in operating activities | $104.4 million | $60.8 million |
- At year-end, cash, cash equivalents and marketable securities totaled $204.2 million, versus $251.3 million in 2021. Current assets were $193.8 million and current liabilities $24.2 million.
- Total liabilities were $35.6 million; these included $15.1 million of operating lease liabilities. The filing reports no off-balance-sheet arrangements and no financial debt balance.
- Comprehensive loss was $123.9 million, including $0.2 million of unrealized losses on marketable securities. Profit margins are not meaningful because the company had no revenue.
Material changes and notable items
- Operating expenses rose 73% year over year. R&D increased 74%, primarily from higher outside services, facility and laboratory costs, and personnel costs. G&A increased 69%, chiefly reflecting employee-related, professional-service and insurance costs.
- In November 2022, Tenaya completed a follow-on offering of common stock and pre-funded warrants, receiving approximately $76.9 million in net proceeds. The offering materially increased shares outstanding; 6.24 million pre-funded warrants were outstanding at year-end. A $75 million at-the-market facility was available, but no shares had been sold under it by year-end.
- Capital expenditures were $20.6 million, primarily for the Union City manufacturing facility. The facility began operations in 2022 and is designed for cGMP AAV manufacturing.
- The 2022 net loss included approximately $11.5 million of stock-based compensation. The company recorded an approximately $2 million employee retention credit receivable, with the benefit reflected in operating expenses.
Pipeline, outlook and principal risks
- TN-201: FDA cleared the IND in January 2023 for a Phase 1b trial in MYBPC3-associated hypertrophic cardiomyopathy. Management expected first patient dosing in Q3 2023 and trial data in 2024. TN-201 has FDA orphan-drug and European orphan-medicinal-product designations.
- TN-301: A Phase 1 trial for the HFpEF candidate was underway. The multiple-ascending-dose stage began in February 2023; data from both stages were anticipated in the second half of 2023.
- TN-401: IND-enabling work was underway, with an IND submission targeted for the second half of 2023. Other programs, including DWORF gene therapy and cardiac reprogramming, remained preclinical.
- Management expected current cash, cash equivalents and investments to fund the operating plan for at least 12 months following the filing. It anticipates increasing expenses and operating losses and says substantial additional funding will be required to complete development and pursue commercialization. No formal financial guidance was provided.
- Key risks include early-stage development and uncertain clinical and regulatory outcomes; possible gene-therapy safety or manufacturing issues; limited patient enrollment; reliance on third parties; competition; intellectual-property challenges; reimbursement uncertainty; and potential dilution or constraints from future financing. The company stated it was not party to material litigation.
- The independent auditor issued an unqualified opinion on the financial statements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Whether TN-201, TN-301 and TN-401 met the disclosed development milestones, and the timing and substance of subsequent clinical data.
- Updated cash, investment balances, operating cash burn and financing needs against the stated minimum 12-month runway estimate.
- Manufacturing readiness, clinical supply, safety monitoring and any regulatory requirements affecting the AAV programs.
- Share-count dilution, including exercise of pre-funded warrants, use of the at-the-market program and any further equity financing.
- Whether preclinical evidence translates into human safety and efficacy, and whether patient access, competition and reimbursement assumptions support commercial potential.